Chronos Therapeutics is a leading CNS specialist company with expertise in degenerative and behavioral diseases of the brain and nervous system. Their main focus is on finding innovative solutions for these complex conditions. Their pipeline includes several groundbreaking programs, including a lead orexin-1 antagonist for addictive behaviors, a novel DAT inhibitor for fatigue in MS, and projects targeting ALS, PTSD, and more.

The company has already achieved positive pre-clinical proof of concept results in these areas, showcasing their commitment to advancing treatment options. In addition to their research and development efforts, Chronos Therapeutics actively seeks new opportunities for in-licensing and collaborations to expand their portfolio and bring cutting-edge therapies to patients. To learn more about their work and explore potential partnerships, visit their website or get in touch with their team.

With their expertise and dedication, Chronos Therapeutics is at the forefront of transforming the landscape of neurological diseases